News In Brief From Elcelyx, Medivir, Repligen
Executive Summary
Elcelyx spins out new company to advance weight-loss supplement while it focuses on delayed-release metformin for type 2 diabetes. Also, Medivir announces promising data for a combination of HCV drugs in patients with advanced fibrosis or cirrhosis of the liver, while Repligen has earned its first milestone under a collaboration in spinal muscular atrophy with Pfizer.